Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy [Eine randomisierte; doppelblinde placebokontrollierte Studie der Phase 2/3 zur Beurteilung der Sicherheit und Wirksamkeit von Davunetide zur Behandlung von progressiver supranukleärer Blickparese]

Next Previous
Trial Profile

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy [Eine randomisierte; doppelblinde placebokontrollierte Studie der Phase 2/3 zur Beurteilung der Sicherheit und Wirksamkeit von Davunetide zur Behandlung von progressiver supranukleärer Blickparese]

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Davunetide (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Allon Therapeutics

Most Recent Events

  • 01 Apr 2022 Results published in the Movement Disorders
  • 16 Sep 2020 Results of post-hoc analysis assessing Correlations between amantadine usage, gait, and cognition in PSP, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders.
  • 24 Apr 2017 Results of a post-hoc analysis from NCT01110720 and NCT01049399 studies, published in the Movement Disorders.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top